Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study

Background There are few reports on conversion surgery (CS) after chemotherapy plus nivolumab as a first-line treatment in patients with unresectable advanced or recurrent gastric cancer (GC). This multicenter study was conducted to analyze real-world data on CS after chemotherapy plus nivolumab as...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2024-12, Vol.31 (13), p.9023-9029
Main Authors: Nakazawa, Nobuhiro, Sohda, Makoto, Hosoi, Nobuhiro, Watanabe, Takayoshi, Kumakura, Yuji, Yamashita, Toshiki, Tanaka, Naritaka, Saito, Kana, Kimura, Akiharu, Kasuga, Kengo, Nakazato, Kenji, Yoshinari, Daisuke, Shimizu, Hisashi, Ubukata, Yasunari, Hosaka, Hisashi, Sano, Akihiko, Sakai, Makoto, Ogawa, Hiroomi, Shirabe, Ken, Saeki, Hiroshi
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers
Biomarkers, Tumor
Chemotherapy
Combined Modality Therapy
Complications
Female
Follow-Up Studies
Gastrectomy
Gastric cancer
Gastrointestinal Oncology
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Minimally invasive surgery
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Nivolumab - administration & dosage
Nivolumab - therapeutic use
Oncology
Patients
Postoperative
Prognosis
Retrospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Surgery
Surgical Oncology
Survival Rate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background There are few reports on conversion surgery (CS) after chemotherapy plus nivolumab as a first-line treatment in patients with unresectable advanced or recurrent gastric cancer (GC). This multicenter study was conducted to analyze real-world data on CS after chemotherapy plus nivolumab as a first-line treatment and to identify predictive biomarkers. Methods This multicenter study included 104 patients who received chemotherapy plus nivolumab as primary treatment for unresectable advanced recurrent GC from 12 institutes. We investigated and analyzed patient characteristics and blood test data in the presence or absence of CS, the relationship between the Gustave Roussy Immune Score (GRIm-s) and CS, and the characteristics of CS cases. Results CS was performed in 12 patients (11.5%). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was significantly better in patients who underwent CS ( p  
ISSN:1068-9265
1534-4681
1534-4681
DOI:10.1245/s10434-024-16161-4